Legend scraps early-stage CAR-T for lymphoma 6 weeks after clinical hold lifted

Legend Biotech has calculated one of its early-stage CAR-T treatments isn’t ready for showtime, scrapping phase 1 plans for a cell therapy that just six weeks ago was freed from a FDA hold.

The decision by Legend to ax LB1901, an autologous chimeric antigen receptor (CAR) T cell therapy to treat relapsed or refractory T-cell lymphoma, boiled down to two factors, according to a SEC filing.